Regenxbio INC Form 4 insider transactions

Chief Legal Officer Patrick J. Christmas reports acquisition of 56,446 shares of REGENXBIO Inc. common stock through a restricted stock unit award.

Argeris N. Karabelas, a director at REGENXBIO Inc., exercised stock options and sold shares of common stock on August 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

REGENXBIO's CEO, Curran Simpson, executed a sale of 100 common stock shares at $15 per share on August 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Chief Scientific Officer of REGENXBIO, Danos Olivier, reports acquisition and disposal of company stock, including purchases through the Employee Stock Purchase Plan and vesting of restricted stock units.

Director Argeris N. Karabelas exercised stock options and sold shares of REGENXBIO Inc. on July 29, 2024, according to a Form 4 filing.

REGENXBIO's CEO, Curran Simpson, sold 9,648 shares of common stock at an average price of $15.04 under a pre-arranged Rule 10b5-1 trading plan.

REGENXBIO director Kenneth T. Mills exercised stock options and sold shares of common stock on July 24 and 25, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Director Kenneth T. Mills of REGENXBIO Inc. reports exercising stock options and selling shares under a pre-arranged Rule 10b5-1 trading plan.

REGENXBIO's CEO, Curran Simpson, was granted stock options and restricted stock units (RSUs) on July 1, 2024, according to a recent SEC filing.

Director Argeris N. Karabelas exercised stock options and sold 10,000 shares of REGENXBIO Inc. common stock on July 1, 2024, according to a recent SEC filing.

Director Jennifer Zachary reports acquisition of common stock and stock options in REGENXBIO Inc.

Director George Migausky reports acquisition of common stock and stock options in REGENXBIO Inc.

Director Argeris N. Karabelas reports acquisition of REGENXBIO stock and options.

Director Alexandra Glucksmann reports acquisition of common stock and stock options in Regenxbio Inc.

Director Jean Bennett reported the acquisition of common stock and stock options in REGENXBIO Inc. on May 31, 2024.

Director Allan M. Fox reported the acquisition of common stock and stock options in REGENXBIO Inc. on May 31, 2024.

Director Daniel Tasse acquired shares and stock options in REGENXBIO Inc. on May 31, 2024.

Director David C. Stump acquired shares of common stock and stock options in REGENXBIO Inc. on May 31, 2024.

REGENXBIO's CEO, Kenneth T. Mills, exercised stock options and sold 15,000 shares of common stock on May 14, 2024, under a pre-arranged Rule 10b5-1 trading plan.

REGENXBIO's CEO, Kenneth T. Mills, exercised stock options and sold 15,000 shares of common stock on April 15, 2024, under a pre-arranged Rule 10b5-1 trading plan.

REGENXBIO's Chief Financial Officer, Vittal Vasista, exercised stock options to acquire 20,041 shares of common stock at $3.76 per share on March 19, 2024.

REGENXBIO's CEO, Kenneth T. Mills, exercised stock options and sold shares on March 14, 2024, under a pre-arranged Rule 10b5-1 trading plan.

REGENXBIO's Chief Medical Officer, Steve Pakola, exercised stock options and sold shares of common stock on March 5, 2024, under a pre-arranged 10b5-1 trading plan.